Peer-reviewed veterinary case report
Short-acting oral fluralaner controls fleas and ticks on dogs
By Bonfim, Isabelle Vilela et al.·Published in Frontiers in veterinary science·2026·Animal Parasitology Department, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of a short-acting oral fluralaner formulation (WellPet™) against fleas and brown dog ticks in controlled and field conditions.
- Species:
- dog
Plain-English summary
A group of dogs was treated with a new short-acting oral medication called fluralaner to control fleas and brown dog ticks. The treatment worked quickly, showing 100% effectiveness against fleas and ticks just two days after administration, and it maintained high efficacy throughout the study period. In a real-world setting, dogs treated with fluralaner showed similar results to those treated with another medication, sarolaner, effectively reducing flea and tick populations without any side effects. This new treatment option could be a great choice for pet owners looking to manage flea and tick infestations.
People also search for: dog flea treatment · fluralaner for ticks · how to get rid of dog fleas fast
Abstract
BACKGROUND: Fluralaner is an isoxazoline widely used for flea and tick control in dogs, mainly in long-acting formulations. However, the performance of short-acting, lower-dose options remains unexplored in scientific literature. This study evaluated the efficacy of a short-acting oral fluralaner formulation (WellPet™-Ourofino Saúde Animal Ltda, São Paulo, Brazil; 10-22.5 mg of fluralaner per kg of body weight) againstandsensu lato under controlled and field conditions in southeastern Brazil. METHODS: A randomized, blinded, negative-controlled laboratory study assessed intrinsic efficacy using standardized artificial infestations over 49 days. A randomized, assessor-blinded positive-controlled field trial compared fluralaner with sarolaner in naturally infested dogs living in private households. Fleas and ticks were counted following WAAVP guidelines. Efficacy was calculated using arithmetic means, and statistical analyses were performed with Mann-Whitney and Wilcoxon tests. All analyses were conducted using IBM SPSS Statistics 31.0. RESULTS: In the controlled study, fluralaner produced a rapid reduction in parasite burdens, achieving 100% efficacy for fleas and ticks as early as Day +2. Efficacy remained between 98.3 and 100% for ticks and 99.7 and 100% for fleas throughout the entire period of evaluation. In the field trial (= 159), both fluralaner and sarolaner markedly reduced parasite loads from Day +7 onward. Efficacy remained above 97% for both parasites in both groups, with no significant differences between treatments at any time point. No product-related adverse events were observed, and the product remained effective even in a region dominated by the tropical lineage ofs.l., recently redescribed as. CONCLUSION: This novel short-acting oral fluralaner formulation demonstrated rapid onset and sustained efficacy under experimental and real-world conditions, supporting its use as an effective option for flea and tick control in areas with high parasite pressure, with an unique periodicity of readministrations every 49 days.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41938774/